Current options for the treatment of idiopathic thrombocytopenic purpura

被引:30
作者
Arnold, Donald M. [1 ]
Kelton, John G. [1 ]
机构
[1] McMaster Univ, Michael G DeGroote Sch Med, Dept Med, Hamilton, ON L8N 3Z5, Canada
关键词
D O I
10.1053/j.seminhematol.2007.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease characterized by low platelets and bleeding. Platelet autoantibodies result in accelerated platelet destruction by the reticuloendothelial cells in the spleen and liver, overwhelming the compensatory capability of the bone marrow to increase platelet production. The goal of treatment for patients with ITP is to raise the platelet count to high enough levels to prevent bleeding using the least toxic therapy, recognizing the generally benign nature of the illness. Corticosteroids, intravenous immune globulin, and splenectomy remain mainstays of treatment; however, newer therapies including rituximab and the thrombopoietin receptor agonists are remodeling conventional treatment algorithms. Immune suppressant medications and cytotoxic drugs continue to be used in patients with severe and chronic refractory ITP with some success; however, estimates of the effect of these and other treatments are limited by the lack of randomized trials using clinical end points. In this article, treatments for ITP are reviewed with a focus on their mechanism of action and the best available evidence from clinical studies. A move towards early aggressive therapy may alter the natural history of this self-perpetuating illness.
引用
收藏
页码:S12 / S23
页数:12
相关论文
共 114 条
[31]  
2-Y
[32]   Medical progress: Immune thrombocytopenic purpura. [J].
Cines, DB ;
Blanchette, VS .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :995-1008
[33]   How I treat idiopathic thrombocytopenic purpura (ITP) [J].
Cines, DB ;
Bussel, JB .
BLOOD, 2005, 106 (07) :2244-2251
[34]   Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine [J].
Clunie, GPR ;
Lennard, L .
RHEUMATOLOGY, 2004, 43 (01) :13-18
[35]   The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts [J].
Cohen, YC ;
Djulbegovic, B ;
Shamai-Lubovitz, O ;
Mozes, B .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (11) :1630-1638
[36]   The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura [J].
Cooper, N ;
Stasi, R ;
Cunningham-Rundles, SS ;
Feuerstein, MA ;
Leonard, JP ;
Amadori, S ;
Bussel, JB .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) :232-239
[37]   IVIg-mediated amelioration of murine ITP via FcγRIIB is independent of SHIP1, SHP-1, and Btk activity [J].
Crow, AR ;
Song, S ;
Freedman, J ;
Helgason, CD ;
Humphries, RK ;
Siminovitch, KA ;
Lazarus, AH .
BLOOD, 2003, 102 (02) :558-560
[38]   Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults - a report on 90 patients [J].
Damodar, S ;
Viswabandya, A ;
George, B ;
Mathews, V ;
Chandy, M ;
Srivastava, A .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (04) :328-331
[39]  
DAN K, 1992, INT J HEMATOL, V55, P287
[40]   Complement activation determines the therapeutic activity of rituximab in vivo [J].
Di Gaetano, N ;
Cittera, E ;
Nota, R ;
Vecchi, A ;
Grieco, V ;
Scanziani, E ;
Botto, M ;
Introna, M ;
Golay, J .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1581-1587